These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31961035)

  • 41. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
    Nilsson IM; Hedner U
    Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A rare case of an acquired inhibitor to factor IX.
    Krishnamurthy P; Hawche C; Evans G; Winter M
    Haemophilia; 2011 Jul; 17(4):712-3. PubMed ID: 21371188
    [No Abstract]   [Full Text] [Related]  

  • 47. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 48. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.
    Cugno M; Mancuso ME; Tedeschi A; Santagostino E; Lorini M; Carbonelli V; Peyvandi F; Mannucci PM
    Haemophilia; 2017 Jul; 23(4):e348-e353. PubMed ID: 28594432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A rare case of late development of inhibitor in haemophilia B with a complex course, and review of the literature.
    Soto I; Martínez D; Ávila LF; Bernardo Á
    Haemophilia; 2018 May; 24(3):e125-e128. PubMed ID: 29488670
    [No Abstract]   [Full Text] [Related]  

  • 50. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 51. The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa.
    Htun KT; McFadyen J; Tran HA
    Ann Hematol; 2014 Oct; 93(10):1785-6. PubMed ID: 24584995
    [No Abstract]   [Full Text] [Related]  

  • 52. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor IX antibody and immune tolerance.
    Warrier I
    Vox Sang; 1999; 77 Suppl 1():70-1. PubMed ID: 10529693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia b and antibodies.
    Nilsson IM; Sundqvist SB; Ljung R; Holmberg L; Freiburghaus C; Björlin G
    Scand J Haematol; 1983 May; 30(5):458-64. PubMed ID: 6190216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
    Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
    Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
    [No Abstract]   [Full Text] [Related]  

  • 56. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.
    Sawamoto Y; Shima M; Yamamoto M; Kamisue S; Nakai H; Tanaka I; Hayashi K; Giddings JC; Yoshioka A
    Thromb Res; 1996 Aug; 83(4):279-86. PubMed ID: 8870172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR
    Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Factor IX inhibitor in hemophilia B presented with anaphylactoid symptoms: report of 3 cases].
    Taketani T; Hanada R; Kawaguchi H; Ida K; Yamamoto K
    Rinsho Ketsueki; 1999 Oct; 40(10):1124-6. PubMed ID: 10565232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.
    Nilsson IM; Berntorp E; Zettervall O
    Proc Natl Acad Sci U S A; 1986 Dec; 83(23):9169-73. PubMed ID: 3491368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.